{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:58:53Z","timestamp":1793177933637,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s10549-023-07217-2","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T14:02:12Z","timestamp":1705327332000},"page":"643-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors"],"prefix":"10.1007","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1700-2411","authenticated-orcid":false,"given":"Alexander S.","family":"Bang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshid","family":"Etaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Arbesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernice Y.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"issue":"10226","key":"7217_CR1","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A (2020) Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395(10226):817\u2013827. https:\/\/doi.org\/10.1016\/S0140-6736(20)30165-3","journal-title":"Lancet"},{"issue":"2","key":"7217_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40257-021-00645-0","volume":"23","author":"E Raschi","year":"2022","unstructured":"Raschi E, Fusaroli M, La Placa M et al (2022) Skin Toxicities with Cyclin-Dependent Kinase 4\/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System. Am J Clin Dermatol 23(2):247\u2013255. https:\/\/doi.org\/10.1007\/s40257-021-00645-0","journal-title":"Am J Clin Dermatol"},{"key":"7217_CR3","doi-asserted-by":"publisher","first-page":"1067264","DOI":"10.3389\/fonc.2023.1067264","volume":"13","author":"M Pasqualoni","year":"2023","unstructured":"Pasqualoni M, Orlandi A, Palazzo A et al (2023) Case report: vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response. Front Oncol 13:1067264. https:\/\/doi.org\/10.3389\/fonc.2023.1067264","journal-title":"Front Oncol"},{"issue":"2","key":"7217_CR4","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/ajco.13585","volume":"18","author":"OB Chan","year":"2022","unstructured":"Chan OB, Su JC, Yazdabadi A, Chan A (2022) Drug induced vitiligo-like depigmentation from a CDK 4\/6 inhibitor. Asia Pac J Clin Oncol 18(2):e154\u2013e156. https:\/\/doi.org\/10.1111\/ajco.13585","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"7217_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10549-020-05914-w","volume":"185","author":"P Sollena","year":"2021","unstructured":"Sollena P, Nikolaou V, Soupos N et al (2021) Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. Breast Cancer Res Treat 185(1):247\u2013253. https:\/\/doi.org\/10.1007\/s10549-020-05914-w","journal-title":"Breast Cancer Res Treat"},{"key":"7217_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231156521","author":"A T\u00fcrkel","year":"2023","unstructured":"T\u00fcrkel A, Kara\u00e7in C, \u00d6ner \u0130, \u015eeyran E, \u00d6ks\u00fczo\u011flu B (2023) Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer. J Oncol Pharm Pract. https:\/\/doi.org\/10.1177\/10781552231156521","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"7217_CR7","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1111\/ijd.16356","volume":"62","author":"M Romagnuolo","year":"2023","unstructured":"Romagnuolo M, Alberti Violetti S, Riva D, Barberi F, Moltrasio C (2023) Vitiligo-like lesions induced by cyclin-dependent kinase 4\/6 inhibitor palbociclib. Int J Dermatol 62(2):e98\u2013e100. https:\/\/doi.org\/10.1111\/ijd.16356","journal-title":"Int J Dermatol"},{"issue":"2","key":"7217_CR8","doi-asserted-by":"publisher","first-page":"e2022045","DOI":"10.5826\/dpc.1202a45","volume":"12","author":"N Silvestre Torner","year":"2022","unstructured":"Silvestre Torner N, Aguilar Mart\u00ednez A, Echarri Gonz\u00e1lez MJ, Tabbara Carrascosa S, Rom\u00e1n Sainz J, Gruber Velasco F (2022) Ribociclib-induced vitiligo: a case report. Dermatol Pract Concept 12(2):e2022045. https:\/\/doi.org\/10.5826\/dpc.1202a45","journal-title":"Dermatol Pract Concept"},{"issue":"4","key":"7217_CR9","doi-asserted-by":"publisher","first-page":"e248782","DOI":"10.1136\/bcr-2022-248782","volume":"15","author":"G Anjaneyan","year":"2022","unstructured":"Anjaneyan G, Keechilat P, Duraisamy P, Eapen M (2022) Ribociclib-induced extensive vitiligo-like lesions: possible pathomechanisms with clinical, dermoscopic and histological correlation. BMJ Case Rep 15(4):e248782. https:\/\/doi.org\/10.1136\/bcr-2022-248782","journal-title":"BMJ Case Rep"},{"issue":"5","key":"7217_CR10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","volume":"76","author":"M Larsabal","year":"2017","unstructured":"Larsabal M, Marti A, Jacquemin C et al (2017) Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol 76(5):863\u2013870. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.044","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"7217_CR11","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3390\/cells10061334","volume":"10","author":"M Garutti","year":"2021","unstructured":"Garutti M, Targato G, Buriolla S, Palmero L, Minisini AM, Puglisi F (2021) CDK4\/6 inhibitors in melanoma: a comprehensive review. Cells 10(6):1334. https:\/\/doi.org\/10.3390\/cells10061334","journal-title":"Cells"},{"issue":"7","key":"7217_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33(7):773\u2013781. https:\/\/doi.org\/10.1200\/JCO.2014.57.4756","journal-title":"J Clin Oncol"},{"key":"7217_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A et al (2019) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 5:5. https:\/\/doi.org\/10.1038\/s41523-018-0097-z","journal-title":"NPJ Breast Cancer"},{"issue":"20","key":"7217_CR14","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 375(20):1925\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1607303","journal-title":"N Engl J Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07217-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-07217-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07217-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T19:22:17Z","timestamp":1711135337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-07217-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["7217"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-07217-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"assertion":[{"value":"23 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approved by Stanford University IRB; approval #61215.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the image in Fig.\u00a0.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}